Literature DB >> 8359178

The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis.

R Corinaldesi1, V Stanghellini, C Tosetti, E Rea, C Corbelli, M Marengo, N Monetti, L Barbara.   

Abstract

The aim of this study was to determine the optimal dosage regimen of cisapride for the treatment of idiopathic gastroparesis. We studied 17 patients with documented idiopathic gastroparesis in a three-way, cross-over, double-blind study with three 4-day treatment periods separated by at least 3 days without treatment. In each period, the patients were preloaded with cisapride (10 mg tid) for three days. On the fourth day (the test day) they took either 10 mg or 20 mg before breakfast and placebo before lunch (1 x 10 mg), (1 x 20 mg), or 10 mg before breakfast and 10 mg before lunch (2 x 10 mg). The medications were taken 30 min before meals. Gastric emptying of solids (99mTc-sulphur colloid) was measured at lunch time under basal conditions and during each treatment period. Plasma concentrations of cisapride were determined before the breakfast dose, before the lunch dose, and at 1, 2, 3, 4 and 5 h after. The greatest acceleration in gastric emptying occurred with the 2 x 10 mg regimen. Although the single morning dose of 20 mg also significantly accelerated gastric emptying (P = 0.05), the reduction was not as substantial. Plasma concentrations of cisapride were significantly higher after 2 x 10 mg than after 1 x 20 mg or 1 x 10 mg. There was a significant relation between cisapride plasma concentrations and changes in gastric emptying. Peak concentrations of cisapride greater than 60 ng.ml-1 were invariably associated with acceleration of gastric emptying. We conclude that cisapride 10 mg tid before meals is the optimal dose for the treatment of idiopathic gastroparesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359178     DOI: 10.1007/bf00315538

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients.

Authors:  P A Testoni; F Bagnolo; L Fanti; S Passaretti; A Tittobello
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

2.  Techniques and errors in scintigraphic measurements of gastric emptying.

Authors:  P Tothill; G P McLoughlin; R C Heading
Journal:  J Nucl Med       Date:  1978-03       Impact factor: 10.057

3.  Analysis of gastric emptying data.

Authors:  J D Elashoff; T J Reedy; J H Meyer
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

4.  Patients with duodenitis have gastric secretory and motor functions like those of duodenal ulcer patients: results of a short-term treatment with ranitidine.

Authors:  R Corinaldesi; A Paternicó; V Stanghellini; G Di Febo; G Biasco; G Caló; N Monetti; C Tosetti; L Barbara
Journal:  J Clin Gastroenterol       Date:  1991-06       Impact factor: 3.062

5.  Effect of cisapride on gastric emptying in dyspeptic patients.

Authors:  J L Urbain; J A Siegel; N C Debie; S P Pauwels
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

6.  Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa.

Authors:  G Stacher; H Bergmann; S Wiesnagrotzki; A Kiss; C Schneider; G Mittelbach; G Gaupmann; J Höbart
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

7.  Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus.

Authors:  M Horowitz; A Maddox; P E Harding; G J Maddern; B E Chatterton; J Wishart; D J Shearman
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

Review 8.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

9.  Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride).

Authors:  R Jian; F Ducrot; C Piedeloup; J Y Mary; Y Najean; J J Bernier
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

10.  Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride.

Authors:  R Jian; F Ducrot; A Ruskone; S Chaussade; J C Rambaud; R Modigliani; J D Rain; J J Bernier
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

View more
  3 in total

Review 1.  Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

Authors:  J R Malagelada; E Distrutti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 2.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 3.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.